Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

The genetic mutation that causes sickle cell anemia also turns red blood cells into potent tumor killers and may offer a new way to treat cancers that are resistant to existing treatments, according to research published January 9, 2013 in the open access journal PLOS ONE by David S. Terman of Jenomic Research Institute and colleagues from Duke University and other institutions.

10 Jan 2013

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Cell Therapeutics, Inc. (CTI) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.

9 Jan 2013

Viewpoints: Health care and the 'crushing federal debt;' Optimism about 'grand bargain;' Iowa's premium increase request

The largest issue America will face in 2013 is health care. And it will only get larger. As the national conversation changes, we'll find that by year-end we're talking about it all the time, whether the ostensible topic is politics, government, the economy, our jobs, or our families. Health care will be the unavoidable topic. Medicare and Medicaid are the biggest element of our most serious national problem: crushing federal debt.

9 Jan 2013

Consumers' perceptions of medical prices can be faulty

Despite advocates' push for more transparency in medical pricing, consumers may draw the wrong message when they know what a health service or good costs.

4 Jan 2013

Concern over transfusions in myocardial infarction patients

A meta-analysis highlights the consistent observational finding that patients with myocardial infarction who receive blood transfusions are at high risk for dying.

28 Dec 2012

Blood transfusion for patients with myocardial infarction associated with increased all-cause mortality

A meta-analysis of 10 studies suggests that receipt of a blood transfusion among patients with myocardial infarction (heart attack) was associated with increased all-cause mortality compared with not receiving a blood transfusion during heart attack, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

25 Dec 2012

Blood transfusion may increase risk of death in heart attack patients with anemia

When heart attack patients present in the emergency department with some degree of anemia, or anemic patients have a heart attack, physicians have a tendency, but not much guidance, about whether to provide a blood transfusion.

25 Dec 2012

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that it has submitted a supplemental new drug application (sNDA) to the United States Food and Drug Administration (FDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use.

25 Dec 2012

Cubist seeks FDA sNDA approval for ENTEREG to accelerate GI recovery

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval for the use of ENTEREG® (alvimopan) to accelerate GI recovery following any surgery that includes a bowel resection with primary anastomosis; expanded from the current indication in patients requiring surgery for colorectal disease.

21 Dec 2012

Amgen to pay $762 million fine for improper drug marketing

Biotech giant Amgen Inc. pleaded guilty in federal court to improper marketing of its anemia drug Aranesp and has agreed to pay $762 million in criminal fines and civil settlements to resolve complaints from company whistle-blowers. Federal prosecutors in New York said the Thousand Oaks company was "pursuing profits at the risk of patient safety" by encouraging doctors to use its popular anemia drug for unapproved uses to boost sales and to take market share from a rival drug maker.

20 Dec 2012

Top-line results from Medivir's simeprevir phase III trials on genotype 1 HCV infection

Medivir AB today announced top-line results from three pivotal phase III trials examining the one pill, once-daily, investigational protease inhibitor, simeprevir (TMC435), administered with pegylated interferon and ribavirin.

20 Dec 2012

Amgen expected to enter a guilty plea to unspecified charges

The biotech giant is expected to plead guilty in a New York federal court criminal case. Some reports suggest the charges relate to "misbranding" -- which refers to the promotion of drugs for uses that have not gained the Food and Drug Administration's approval.

19 Dec 2012

Two cups of milk per day is enough to maintain adequate vitamin D levels for children

New research has answered one of the most common questions parents ask their doctors: How much milk should I be giving my children? The answer is two cups per day.

18 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

High-risk leukemia patients respond to novel drug

A third of adult leukemia patients given the novel drug quizartinib during a phase II study have achieved a composite response of either complete remission, or remission with incomplete platelet recovery or incomplete hematologic recovery, report US researchers.

14 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Anemia News and Research

Further Reading

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Viewpoints: Health care and the 'crushing federal debt;' Optimism about 'grand bargain;' Iowa's premium increase request

Consumers' perceptions of medical prices can be faulty

Concern over transfusions in myocardial infarction patients

Blood transfusion for patients with myocardial infarction associated with increased all-cause mortality

Blood transfusion may increase risk of death in heart attack patients with anemia

AMAG seeks FDA sNDA approval for Feraheme Injection

Cubist seeks FDA sNDA approval for ENTEREG to accelerate GI recovery

Amgen to pay $762 million fine for improper drug marketing

Top-line results from Medivir's simeprevir phase III trials on genotype 1 HCV infection

Amgen expected to enter a guilty plea to unspecified charges

Two cups of milk per day is enough to maintain adequate vitamin D levels for children

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

High-risk leukemia patients respond to novel drug

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News